- Home
- VRSN vs MRNA Comparison
VRSN vs MRNA Comparison
Compare VRSN & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRSN | MRNA |
|---|---|---|
| Founded | 1995 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1B | 26.7B |
| IPO Year | 1997 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VRSN | MRNA |
|---|---|---|
| Price | $258.89 | $82.42 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 12 |
| Target Price | ★ $317.67 | $34.27 |
| AVG Volume (30 Days) | 801.6K | ★ 8.5M |
| Earning Date | 04-23-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.19% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 6.24 | N/A |
| Revenue | $1,656,600,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $6.78 | $9.36 |
| Revenue Next Year | $5.37 | $15.43 |
| P/E Ratio | $41.54 | ★ N/A |
| Revenue Growth | ★ 6.37 | 4.29 |
| 52 Week Low | $209.34 | $22.28 |
| 52 Week High | $312.48 | $85.60 |
Technical Indicators
Market Signals| Indicator | VRSN | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 41.02 | 81.17 |
| Support Level | $255.89 | $45.69 |
| Resistance Level | $283.11 | N/A |
| Average True Range (ATR) | 7.83 | 5.86 |
| MACD | -0.20 | 2.36 |
| Stochastic Oscillator | 38.66 | 90.69 |
Price Performance
Historical ComparisonAbout VRSN VeriSign Inc.
Verisign is an operator of critical infrastructure within the domain name system, or DNS. As the registry for some of the world's most popular TLDs, .com and .net, Verisign directs DNS resolvers to the appropriate registry where IP addresses are stored. Verisign's control over its TLDs is regulated by ICANN and the NTIA and are subject to contract renewal every six years. The company generates revenue through annual subscriptions allowing customers to use .com and .net as their TLD of choice for their respective websites.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.